EMCUREPharmaceuticals
Emcure Pharmaceuticals Ltd — Cash Flow Statement
₹1595.50
+4.14%
Emcure Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Free Cash Flow | 444.78 Cr | 790.11 Cr | 343.49 Cr | 371.22 Cr | — |
| Repayment Of Debt | -883.30 Cr | -482.29 Cr | -342.73 Cr | -446.70 Cr | — |
| Issuance Of Debt | 0.00 | 547.43 Cr | 357.59 Cr | 371.42 Cr | — |
| Issuance Of Capital Stock | 779.23 Cr | -12.58 Cr | 0.00 | 0.00 | — |
| Capital Expenditure | -406.93 Cr | -307.13 Cr | -403.36 Cr | -396.99 Cr | — |
| End Cash Position | -14.31 Cr | 43.99 Cr | -174.53 Cr | -308.17 Cr | — |
| Beginning Cash Position | 43.99 Cr | -174.53 Cr | -308.17 Cr | -350.04 Cr | — |
| Effect Of Exchange Rate Changes | -2.05 Cr | -2.00 Cr | -0.13 Cr | 0.19 Cr | — |
| Changes In Cash | -56.25 Cr | 220.52 Cr | 133.77 Cr | -172.44 Cr | — |
| Financing Cash Flow | -813.96 Cr | -164.21 Cr | -145.40 Cr | -151.85 Cr | — |
| Interest Paid Cff | -128.68 Cr | -208.18 Cr | -178.56 Cr | -155.32 Cr | — |
| Common Stock Dividend Paid | 0.00 | -54.26 Cr | -36.17 Cr | -54.26 Cr | — |
| Net Common Stock Issuance | 779.23 Cr | -12.58 Cr | 0.00 | 0.00 | — |
| Common Stock Issuance | 779.23 Cr | -12.58 Cr | 0.00 | 0.00 | — |
| Net Income From Continuing Operations | 971.35 Cr | 727.23 Cr | 747.22 Cr | 972.55 Cr | — |
| Net Issuance Payments Of Debt | -1.41K Cr | 167.68 Cr | 112.54 Cr | 100.62 Cr | — |
| Net Short Term Debt Issuance | -522.50 Cr | 102.54 Cr | 97.68 Cr | 175.90 Cr | — |
| Short Term Debt Payments | -522.50 Cr | — | — | — | — |
| Net Long Term Debt Issuance | -883.30 Cr | 65.14 Cr | 14.86 Cr | -75.28 Cr | — |
| Long Term Debt Payments | -883.30 Cr | -482.29 Cr | -342.73 Cr | -446.70 Cr | — |
| Long Term Debt Issuance | 0.00 | 547.43 Cr | 357.59 Cr | 371.42 Cr | — |
| Investing Cash Flow | -94.00 Cr | -712.51 Cr | -467.69 Cr | -788.79 Cr | — |
| Interest Received Cfi | 23.14 Cr | 17.95 Cr | 5.24 Cr | 5.95 Cr | — |
| Net Investment Purchase And Sale | 259.18 Cr | -109.79 Cr | -70.84 Cr | -105.79 Cr | — |
| Sale Of Investment | 986.13 Cr | 889.49 Cr | 194.11 Cr | 138.01 Cr | — |
| Purchase Of Investment | -726.95 Cr | -999.28 Cr | -264.95 Cr | -243.80 Cr | — |
| Net Business Purchase And Sale | 0.00 | -345.07 Cr | 0.00 | -300.08 Cr | — |
| Purchase Of Business | 0.00 | -345.07 Cr | 0.00 | -300.08 Cr | — |
| Net Intangibles Purchase And Sale | -185.16 Cr | -31.36 Cr | -12.77 Cr | -18.79 Cr | — |
| Purchase Of Intangibles | -185.16 Cr | -31.36 Cr | -12.77 Cr | -18.79 Cr | — |
| Net PPE Purchase And Sale | -191.17 Cr | -244.24 Cr | -389.32 Cr | -375.08 Cr | — |
| Sale Of PPE | 30.60 Cr | 31.54 Cr | 1.27 Cr | 3.12 Cr | — |
| Purchase Of PPE | -221.77 Cr | -275.77 Cr | -390.60 Cr | -378.20 Cr | — |
| Operating Cash Flow | 851.71 Cr | 1.10K Cr | 746.85 Cr | 768.21 Cr | — |
| Taxes Refund Paid | -246.86 Cr | -223.65 Cr | -200.48 Cr | -311.18 Cr | — |
| Change In Working Capital | -424.30 Cr | 50.52 Cr | -292.24 Cr | -291.91 Cr | — |
| Change In Other Current Liabilities | -4.05 Cr | 56.22 Cr | 23.34 Cr | -18.08 Cr | — |
| Change In Other Current Assets | -49.70 Cr | 10.39 Cr | -4.40 Cr | -123.36 Cr | — |
| Change In Payable | 170.21 Cr | 154.26 Cr | -39.18 Cr | 315.70 Cr | — |
| Change In Inventory | -406.71 Cr | -26.76 Cr | 66.39 Cr | -307.16 Cr | — |
| Change In Receivables | -143.44 Cr | -150.61 Cr | -339.79 Cr | -172.87 Cr | — |
| Other Non Cash Items | 159.96 Cr | 214.82 Cr | 198.80 Cr | 163.28 Cr | — |
| Stock Based Compensation | 1.99 Cr | 3.97 Cr | 5.28 Cr | 5.72 Cr | — |
| Depreciation And Amortization | 384.13 Cr | 312.41 Cr | 260.12 Cr | 244.85 Cr | — |
| Amortization Cash Flow | 99.78 Cr | 62.78 Cr | 52.32 Cr | 53.37 Cr | — |
| Depreciation | 284.35 Cr | 249.63 Cr | 207.79 Cr | 191.49 Cr | — |
| Gain Loss On Investment Securities | -5.80 Cr | -2.53 Cr | -0.12 Cr | — | — |
| Net Foreign Currency Exchange Gain Loss | 49.47 Cr | 21.68 Cr | 27.94 Cr | -15.52 Cr | — |
| Gain Loss On Sale Of PPE | -38.23 Cr | -7.19 Cr | 0.33 Cr | 0.41 Cr | — |
| Cash Dividends Paid | — | -54.26 Cr | -36.17 Cr | -54.26 Cr | -18.09 Cr |
| Short Term Debt Issuance | — | 102.54 Cr | — | — | — |
| Net Other Investing Changes | — | 10000.00 | — | 5.00 Cr | — |
| Other Cash Adjustment Outside Changein Cash | — | — | — | 214.12 Cr | — |
| Net Other Financing Charges | — | — | — | — | 11.40 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Emcure Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.